VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myelomaKalyan Nadiminti, Guido Tricot, Lindsay Dozeman et al.|OncoTargets and Therapy|2017Cited by 5
A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety and Response Results from the Prospective Phase II Trial (NCT01849783)Kalyan Nadiminti, Yogesh Jethava, Christopher Strouse et al.|Blood|2018Cited by 5
Incidence of Fungal Infections Associated with the Use of Novel Agents As Part of Conditioning Regimen during Autologous Stem Cell Transplant in Multiple Myeloma; A Single Center Experience at the University of IowaKalyan Nadiminti, Guido Tricot, Sree Pilla et al.|Transplantation and Cellular Therapy|2017Cited by 3
Impact of Chemotherapy Based Induction Using Dexamethasone, Cisplatin, Doxorubicin, Cyclophosphamide and Etoposide (DPACE) Versus Novel Agent Induction in Patients Undergoing Tandem Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)Kalyan Nadiminti, Yogesh Jethava, Christopher Strouse et al.|Transplantation and Cellular Therapy|2019Cited by 3
A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome predictionKalyan Nadiminti, Sarah L. Mott, Kimberly J. Langer et al.|Blood Cancer Journal|2021Cited by 2